Elastokines are Associated with a Poor Prognosis in Idiopathic Pulmonary Fibrosis.

Background: During the development of idiopathic pulmonary fibrosis (IPF), elastin is broken down and replaced with a stiffer substrate which interferes with normal breathing. This remodeling process releases the amino acids desmosine and isodesmosine and elastin degradation products (EDP), collectively known as elastokines, into the circulation and may act as a surrogate for the degree of matrix turnover. We examined the association between circulating and urinary elastokine concentrations, lung function, and transplant-free survival. Research question: What are the associations between circulating and urinary elastokine concentrations (a marker of mature elastin turnover) with disease progression, as measured by transplant-free survival, in IPF? Study Design and Methods: Concentrations of desmosine and isodesmosine (elastokines) were measured via enzyme linked immunosorbent assay (ELISA) in the urine and serum of healthy volunteers and those with IPF. Samples were obtained from the University of Rochester Medical Center Interstitial Lung Disease (ILD) registry/biorepository (n = 81 with IPF and 24 healthy volunteers). We used linear and logistic regression modeling to determine associations between changes in urine EDP concentrations and lung function. Secondary analyses included the effect of anti-fibrotic medications on EDP concentration and assessment of associations between EDP concentrations at the time of diagnosis, lung function, and clinical outcomes. Results: Patients with IPF were older, more likely to be male, had ever smoked, and had worse lung function compared to healthy volunteers (p value <0.02 for all parameters). Patients with IPF had higher concentrations of elasotkines (p <0.001), and among those with IPF, higher elastokine concentrations were associated with reduced forced vital capacity (FVC, p = 0.026), and decreased three-year transplant-free survival (p=0.0005). Interpretation: Circulating and urinary elastokines are biomarkers of matrix turnover and are associated with relevant clinical outcomes in patients with IPF.